Ketamine and the Disinhibition Hypothesis: Neurotrophic Factor-Mediated Treatment of Depression.
Pharmaceuticals (Basel, Switzerland) May 12, 2023 Philip Borsellino, Reese I. Krider, Deanna Chea et al.
Ketamine is a promising alternative to traditional pharmacotherapies for major depressive disorder, treatment-resistant depression, and other psychiatric conditions that heavily contribute to the global disease burden. In contrast to the current standard of care medications for these disorders, ketamine offers rapid onset, enduring clinical efficacy, and unique therapeutic potential for use in...